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Major histocompatibility complex antigens that provoke severe transplant reactions are
referred to as the human leukocyte antigen (HLA) in human and as the H-2 in mice. Even
if the donor and recipient are HLA-identical siblings, graft-versus-host reactions have been
linked to differences in the minor histocompatibility antigen. As the chance of ﬁnding
an HLA-identical sibling donor is only 25%, attention has been focused on using alter-
native donors. An HLA-mismatched donor with non-inherited maternal antigens (NIMA)
is less immunogenic than that with non-inherited paternal antigens, because the con-
tact between the immune systems of the mother and child during pregnancy affects
the immune response of the child against NIMA. However, the immunologic effects of
developmental exposure to NIMA are heterogeneous, and can be either tolerogenic or
immunogenic. We recently have devised a novel method for predicting the tolerogenic
effect of NIMA. In this review, we overview the evidence for the existence of the NIMA
tolerogenic effect, the possible cellular and molecular basis of the phenomenon, and its
utilization in hematopoietic stem cell transplantation.We suggest a future direction for the
safe clinical use of this phenomenon, fetomaternal tolerance, in the transplantation ﬁeld.
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INTRODUCTION
More than 50 years ago, Owen et al. (1954) made the remark-
able discovery that most twin cattle were born with a stable
mixture of each other’s red cells. Claas et al. (1988) later found
that human leukocyte antigen (HLA) broadly sensitized patients
commonly failed to produce antibodies against mismatched non-
inherited maternal antigens (NIMA), but were fully capable of
producing anti-non-inherited paternal antigens (NIPA). The def-
inition of NIMA or NIPA is based on an offspring-based HLA
haplotype that is not inherited from the mother or father, respec-
tively. Billingham et al. (1953) then showed that injection of
allogeneic splenocytes from murine fetuses enabled the accep-
tance of later skin grafts from the same donor. This phenomenon
is now referred to as fetomaternal tolerance, and suggests that
perinatal exposure to NIMA may affect the developing immune
system of neonates. These phenomena have been clinically utilized
in organ transplantation and allogeneic hematopoietic stem cell
transplantation (HSCT; Burlingham et al., 1998; van Rood et al.,
2002). Burlingham et al. (1998) showed the superior graft survival
rate in NIMA- compared to NIPA-mismatched renal transplant
recipients from sibling donors. Furthermore, van Rood et al.
(2002) demonstrated that HSCT from NIMA-mismatched sibling
donors showed a lower incidence of severe acute graft-versus-
host disease (GVHD) compared with that from the other family
donors. Ichinohe et al. (2004) have demonstrated the feasibility
of HLA-haploidentical HSCT from NIMA-mismatched relatives
without T cell depletion. These clinical studies have been per-
formed based on the presence of fetomaternal microchimerism as
a result of fetomaternal immunological tolerance. Nevertheless,
some cases developed severe acute GVHD despite the existence
of microchimeric cells (Kanda et al., 2009). We recently reported
that NIMA effects directed toward the major histocompatibil-
ity complex (MHC) antigen were divided into immunogenic
and tolerogenic reactivities (Araki et al., 2010). These effects
were correlated with maternal microchimerism. The reactivi-
ties were predictable by an MLR-ELISPOT (mixed lymphocyte
reaction; enzyme linked immunospot) assay. We found that
non-T cell-depleted (TCD) NIMA-mismatched haploidentical
HSCT could be performed safely by evaluating the reaction
of IFN-γ-producing cells of the donors against NIMA before
transplantation.
HISTOCOMPATIBILITY ANTIGENS IN HUMANS AND MICE
Alloantigens can be divided into MHC antigen and minor histo-
compatibility antigen (MiHA), the former being responsible for
eliciting the strongest immune responses to allogeneic tissues. The
MHC is referred to as the HLA complex in humans and as the
H-2 complex in mice (Table 1). The genes related to the HLA sys-
tem encode a complex array of histocompatibility molecules that
play a central role in immune responsiveness and in determining
the outcome of HSCT in humans (Beatty et al., 1993; Petersdorf
et al., 1995). The primary goal of histocompatibility testing for
patients who are undergoing HSCT is the identiﬁcation of a suit-
able HLA-matched donor to reduce the risk of post-transplant
complications, which may result from HLA incompatibility.
The MHC identity of the donor and host is not the sole fac-
tor determining the immunological reactivity in HSCT. When
transplantation is performed in an unrelated setting, even if the
MHC antigens of donor are identical to those of recipient, con-
siderable transplant reactions may occur because of differences
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Table 1 | Histocompatibility antigens in humans and mice.
Human Mouse
MHC antigen
Class I A, B, C K, D, L
Class II DR, DQ, DP IA, IE
MiHA
Y chromosome SMCY, UTY, DBY, DFFRY, HY (Smcy), HY (Uty),
related RPS4Y, TMSB4Y HY (Dby)
Autosomal HA-1, HA-2, HA-3, HA-8, HB-1, H3, H4, H7, H13,
chromosome ACC-1, ACC-2, UGT2B17, LRH-1, H28, H46, H47, H60
related CTSH, ECGF1, PANE1, SP110,
SLC1A5, SLC19A1, P2RX7
at various minor histocompatibility loci. MiHAs, peptides derived
frompolymorphic proteins, are capable of eliciting cellular alloim-
mune responses in vitro and in vivo. Their immunogenicity arises
as a result of their presentation in the context of MHC class I
or II, where they are recognized by alloreactive MHC-restricted
T cells. The most important immune reactions elicited by in vivo
alloreactivity to MiHA are graft rejection and acute GVHD.
To date, human MiHAs have not been fully characterized,
although some murine MiHAs have been compared with the
human counterparts (Table 1). Immunological targeting of HY
proteins results in a relatively high incidence of acute GVHD when
male recipients receive HSCT from female donors (Stern et al.,
2006). While approximately one-third of the known MiHAs are
encoded on theY chromosome, many MiHAs are located on auto-
somal chromosomes. A genetic linkage analysis has been used to
deﬁne the genomic regions encoding the MiHAs (Akatsuka et al.,
2003; de Rijke et al., 2005). With the recent introduction of more
advanced analytical techniques,more human MiHA epitopes have
been identiﬁed (Van Bergen et al., 2010; Sellami et al., 2011).
CLINICAL SIGNIFICANCE OF NON-INHERITED
MATERNAL ANTIGEN
Graft survival in HSCT is optimal when the donor and recipient
are HLA-identical. However, in some situations, if this is not pos-
sible, haploidentical siblings, parents, and offspring are considered
as potential donors. Contact between the mother and child dur-
ing pregnancy can lead to tolerization, and subsequently have an
additional beneﬁt on the transplant outcome. A new nomencla-
ture was proposed to assign the haplotypes of a family in which
one of the siblings is a potential transplant donor (van Rood and
Claas, 2000) as depicted in Figure 1. The parents or siblings that
share one haplotype with the recipient and differ for the other
haplotype are potential donors. The patient inherits the inher-
ited maternal HLA antigens (IMA) haplotype from the mother,
and the inherited paternal HLA antigens (IPA) from the father.
When the patient is transplanted from one of the parents or from
a haploidentical sibling, the NIMA or NIPA is the mismatched
haplotype. This nomenclature scheme can also be used in cases
where the mother or father is the potential donor (Figure 1).
FIGURE 1 | Significance of non-inherited maternal antigen in
transplantation.The nomenclature of the HLA haplotype is
patient-oriented in the transplantation ﬁeld. Children inherit one haplotype
from each of parent. Siblings of the patient share one haplotype with the
donor, and the other haplotype is the non-inherited haplotype. The HLA
haplotypes in parentheses are shown as representative examples.When
the patient is transplanted with donor from one of the parents or from a
haploidentical sibling, the non-inherited maternal HLA antigens (NIMA) or
non-inherited paternal HLA antigens (NIPA) are the mismatched haplotype.
The NIMA and NIPA-mismatched siblings can be potential donors.
Because of the existence of fetomaternal tolerance, NIPA is more
immunogenic thanNIMA.Therefore, the order of donor eligibility
is IMA/IPA, NIMA/IPA followed by IMA/NIPA.
Several studies have been performed to investigate the inﬂuence
of non-inherited and inherited parental antigens on transplanta-
tion, and tolerizing effects (a NIMA effect) have been described.
In HSCT, van Rood et al. (2002) and Ichinohe et al. (2004) showed
that the patients who received non-TCD BMT from a NIMA-
mismatched donor had a signiﬁcantly lower incidence of acute
GVHD than a NIPA-mismatched donor. However, even in non-
TCD BMT from a NIMA-mismatched donor, 10% of patients
still experienced severe acute GVHD (Ichinohe et al., 2004). Fur-
thermore, graft rejection and hyperacute GVHD after HSCT
from NIMA-mismatched siblings have been observed in spite of
the fact that maternal microchimerism was detected (Okumura
et al., 2007). On the other hand, Kanda et al. (2009) described
that a substantial proportion of long-term survivors after NIMA-
mismatched HSCT could discontinue the administration of
immunosuppressive agents, despite the frequent occurrence of
moderate to severe chronicGVHD.Therefore, amethod that could
evaluate this unpredictable NIMA effect was desired.
MURINE MODELS FOR MAJOR AND MINOR
HISTOCOMPATIBILITY ANTIGENS TO NIMA
There have been several investigations of NIMA in murine models
(Burlingham et al., 1998; Andrassy et al., 2003). The immunologi-
cal effects of developmental exposure to NIMA are heterogeneous
(Mold et al., 2008; Molitor-Dart et al., 2008;Verhasselt et al., 2008).
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The precise mechanisms underlying the heterogeneity are still
under investigation. The relevance of MiHA in the NIMA effect
has not been reported. Not only in the MHC-identical, but also
underMHC-haploidentical conditions,MiHAalloreactivitiesmay
be induced upon transplantation (Verdijk et al., 2004). Therefore,
focusing on the NIMA effect separated by the MHC (H-2) and
MiHA responses is clinically relevant.
The mouse MiHA loci confer a wide range of immunogenicity,
ranging from weakly to strongly immunogenic (Table 1; Men-
doza et al., 1997; Choi et al., 2001; Roopenian et al., 2002). Recent
studies have provided evidence that GVHD could be caused by
a limited number of MiHA, including H4, H7, H13, H28, H60,
and H-Y (Eden et al., 1999; Choi et al., 2002; Yang et al., 2003).
The immunodominance of these MiHA was manifested on genet-
ically varied backgrounds among B10, BALB/c, and DBA/2 strains
(Sanderson and Frost, 1974; Mendoza et al., 1997; Malarkannan
et al., 2000). So far, there has been no report distinguishing H-2
from MiHA with regard to NIMA. We have classiﬁed mouse mod-
els of NIMA based on the major and minor histocompatibility
antigens to NIMA (Hirayama and Azuma, 2011). In our study,
B10 congenic mice were used as NIMA models and the MiHA
matched entirely in this system (Figure 2B). On the other hand,
in the conventional model (Figure 2A), the NIMA includes not
only non-inherited H-2, but also non-inherited MiHA. Therefore,
FIGURE 2 | Murine models for non-inherited maternal antigens.
(A) Left, C57BL/6 (B6) males (H-2b/b) were mated with (B6 × DBA/2) F1
females (H-2b/d), thus exposing the H-2b/b offspring in utero and via
breastfeeding to NIMAd antigens. Right, (B6 × DBA/2) F1 males were
mated with B6 females, creating H-2b/b backcross offspring that had not
been exposed to “d,” as reported by Andrassy et al. (2003). (B) Left,
B10.BR males (H-2k) were mated with (B10.D2 × B10) F1 females (H-2d/b),
thus exposing the H-2d/k type offspring to NIMAb, and H-2b/k type
offspring to NIMAd. Right, (B10.D2 × B10) F1 males (H-2d/b) were
mated with B10.BR females (H-2k), creating the controls; both H-2d/k
and H-2b/k type offspring that had not been exposed to “b” and “d,”
respectively. These mice have a B10 background, in other words, their
MiHA are matched, and the H-2 antigens are mismatched for both
class I and II.
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our NIMA model, but not the conventional NIMA model, did not
affect the immunogenicity of MiHA.We examined the tolerogenic
potential of NIMA-exposure for H-2 of class I and II disparities
without any inﬂuences of the MiHA (Araki et al., 2010). Con-
trary to previous reports that showed an apparent NIMA effect
(Andrassy et al., 2003; Aoyama et al., 2009), we found no evi-
dence of the NIMA effect (Araki et al., 2010). The reason for the
difference remains to be determined, but it could be due to the
abrogation of the MiHA effect in our system (Figure 2B).
MATERNAL MICROCHIMERISM AND FETOMATERNAL
TOLERANCE
The bidirectional exchange of cells, both mature and progeni-
tor types, at the maternal–fetal interface is a common feature of
mammalian reproduction (Lo et al., 1996). The presence of semi-
allogeneic cells in a host can have signiﬁcant immunological effects
on transplantation tolerance and rejection. Maternal cells and
DNA were detected for a long time after parturition in the periph-
eral blood and lymphoid organs of offspring (Maloney et al., 1999;
Andrassy et al., 2003). Breastfeeding during the neonatal period
also might contribute to building-up maternal microchimerism in
the offspring, because breast milk is rich in soluble maternal MHC
antigens (Verhasselt et al., 2008; Aoyama et al., 2009). Maternal
microchimerism may cause tolerance, resulting in the acceptance
of an allograft bearing antigens shared by the microchimeric
cells. However, microchimerism may also cause sensitization, thus
resulting in rejection. Distinguishingwhich of these effects is likely
to occur prior to the transplant may revolutionize the ﬁeld of
living-related renal transplantation, wherein microchimerism can
exert a powerful inﬂuence on graft outcome (van Rood et al.,
2002). Long-term maternal microchimerism is easily detected
from the peripheral blood or various tissues, including the skin,
liver, and thyroid gland, by using highly sensitive polymerase chain
reaction-based techniques (Ichinohe et al., 2002). Although many
investigators have suggested the association of long-term maternal
and fetal microchimerism with the development of autoimmune
diseases, including systemic sclerosis, primary biliary cirrhosis,
juvenile inﬂammatory myopathies, and biliary atresia (Nelson,
2003; Suskind et al., 2004), it is difﬁcult to establish a precise etio-
logical link, becausematernalmicrochimerism is frequently found
in healthy females with a history of uncomplicated pregnancy,
and in more than two-thirds of immunocompetent individuals
without any manifestations of autoimmune attacks (Kodera et al.,
2005). Moreover, Ko et al. (1999) suggested that passenger leuko-
cytes were involved in the induction phase of allograft acceptance
andmicrochimerism in the thymus, but not in the blood, andwere
also associated with allograft survival. These results suggest that
microchimerism may play a role in allograft survival, but that the
persistence of peripheral microchimerism is not required.
Several mechanisms of fetomaternal tolerance have so far been
reported. One possiblemechanism is the clonal deletion of NIMA-
speciﬁc lymphocytes. Vernochet et al. (2005) described partial
deletion of B cells having high afﬁnity for the NIMA. However,
B cells having low afﬁnity for the NIMA were not clonally deleted.
Bemelman et al. (1998) showed central and peripheral deletion of
donor-speciﬁc T cells after establishing mixed chimerism in the
recipient with a high dose of bone marrow cells. Low doses of
bone marrow cells induced a form of tolerance that was regula-
tory T cells (Treg)-dependent, consistent with the establishment
of microchimerism rather than mixed chimerism. Bonilla et al.
(2006) described that deletion of effector T cells due to a form of
suppressivemicrochimerism in antigen-presenting cells was a con-
sequence of the establishment of a dominant Treg-population in
the host. Therefore, fetomaternal tolerance could not be explained
only by the clonal deletion mechanism.
Another possible mechanism is the induction of Treg for
NIMA. Tsang et al. (2008) described the possibility of inducing
NIMA-speciﬁc Treg in the direct and indirect presentation of
maternal microchimerism. On the other hand, since oral tol-
erance is known to generate TGF-β-producing Treg (Gonnella
et al., 2003), oral exposure to maternal MHC antigens present
in breast milk (Molitor et al., 2004) may generate NIMA-speciﬁc
Treg, which may prevent the deletion of maternal cells by NIMA-
speciﬁc effectorT cells, resulting in ahigh level of microchimerism.
Aoyama et al. (2009) reported that exposure toNIMAboth in utero
and by breastfeeding appears to generate higher levels of mater-
nal microchimerism than in utero exposure alone, and that the
degree of microchimerism, correlates with a prolonged survival in
maternal heart grafts.
PREDICTION OF ACUTE GVHD IN HLA-MISMATCHED HSCT
Predicting acute GVHD in vitro before transplantation has been
tried in an HLA-mismatched setting, but satisfactory methods
had not been established. The frequencies of cytotoxic T lym-
phocyte precursor (CTLp) and helper T lymphocyte precursor
(HTLp) cells, as well as MLR, were reported for the methods that
had been evaluated to detect an individual’s reactivity to NIMA
in vitro (Falkenburg et al., 1996; Moretta et al., 1999; Tsafrir et al.,
2000). Moretta et al. (1999) described that the frequency of NIMA-
speciﬁcCTLp in cord blood samples could bemeasured in order to
better deﬁne the phenomenon of NIMA tolerance. NIMA-reactive
cord blood cells were detectable, but the authors of that study
could not show a difference in the CTLp frequency toward NIMA
and NIPA. Falkenburg et al. (1996) investigated whether NIMA
tolerance could allow transplantation over certain HLA barriers.
Neither the CTLp nor HTLp frequencies against NIPA were not
signiﬁcantly different from those against NIMA. Indeed, Kircher
et al. (2004) showed that the CTLp andHTLp frequencies were not
predictive for the risk of acuteGVHDinpatientswho received allo-
geneicHSCT.Collectively, established test systems are not available
for predicting an alloreaction and the outcome after HSCT. CTLp
reﬂects the alloreactivity of class I mismatch, and MLR and HTLp
reﬂect alloreactivity of class II mismatch. Levitsky et al. (2009)
reported an evaluation of allogeneic reactions that used Treg. They
generated carboxyﬂuorescein diacetate succinimidyl ester-labeled
CD4+CD25high FOXP3+ cells in MLR, which they called “Treg
MLR,” with varying HLA disparities and cell components. How-
ever, this method reﬂects only differences in MHC class II. Thus,
all of the above-mentioned methods can detect MHC class I or
class II separately, but it is difﬁcult to detect them simultaneously
(Table 2). We recently, reported a novel method, MLR-ELISPOT
assay, that overcomes these disadvantages, as shown in Figure 3A.
The alloreactivities of NIMA-exposed mice and NIMA-non-
exposed mice were evaluated by MLR, and we found a wide range
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Table 2 | Assays to detect allogeneic antigens.
Assay Target antigen
Frequency of cytotoxic T lymphocyte precursor MHC class I
Frequency of helper T lymphocyte precursor MHC class II
Mixed lymphocyte reaction (MLR), modiﬁed MLR MHC class II
Regulatory T lymphocyte MLR MHC class II
MLR-ELISPOT for interferon-γ MHC class I and II
(MiHA)
FIGURE 3 | Prediction of the reactivity to NIMA by the MLR-ELISPOT
assay. (A)The ELISPOT assay combined with MLR (MLR-ELISPOT) is a
sensitive functional assay to detect alloreactivity for both major and minor
histocompatibility antigens in mice. (B)The mice were classiﬁed into two
groups based on their reactivity to NIMA; the high responders
(HR ≥ mean ± 1 SD in NIMA-non-exposed) or the low responders
(LR < mean ± 1 SD) group by using MLR (Araki et al., 2010). The
IFN-γ-producing ability before the induction of GVHD was presented by the
MLR-ELISPOT assay. Peripheral blood mononuclear cells from
NIMA-exposed LR mice (n = 8), NIMA-exposed HR mice (n = 7), and
non-exposed mice (n = 6) were stimulated with B10 mouse peripheral
blood mononuclear cells. The data are expressed as the means ± SD of
individual animals. *p < 0.05.
of reactivity (Araki et al., 2010). This indicates that the fetoma-
ternal interaction acts on both tolerance (low-responder, LR) and
sensitization (high-responder, HR; Molitor-Dart et al., 2008; van
Halteren et al., 2009). The reports from Falkenburg et al. (1996)
and Tsafrir et al. (2000) detected a reactivity to NIMA by MLR,
and CTLp and HTLp, respectively. Interestingly, when we scru-
tinized the ﬁgures in their articles, the individual reactivities of
the NIMA-exposed group showed a wider range than the control
group, and those reactivities seem to be divided into low and high
reactions, although the authors of those studies did not discuss
these observations. This was a further indication that reactivity
to NIMA could be detected in vitro, and that the fetomaternal
interaction promoted either tolerance or sensitization.
Recently, we demonstrated that the number of cells produc-
ing IFN-γ was signiﬁcantly lower in the NIMA-exposed LR group
than the HR group by using an MLR-ELISPOT assay in a murine
model (Figure 3B). Thus, the capacity for an individual to produce
IFN-γ against allogeneic antigens or NIMA could differentiate LR
from HR. This assay is easily applicable in humans, and is a versa-
tile method to detect reactivities to MHC class I, as well as class II.
Moreover, its detectionmay reﬂect the reactivity toMiHA. In other
words, this assay might be useful to predict the total immunolog-
ical reaction of donor T cells to the recipient in HLA-mismatched
HSCT.
CONCLUSION
Non-inherited maternal antigens-mismatched haploidentical
HSCT has been progressing, and now can lead to sustained
engraftment, lower early treatment-related mortality, and accept-
able rates of acute GVHD. However, it is difﬁcult to predict severe
acuteGVHDprior to transplantation. Our recent report addressed
this issue (Araki et al., 2010). The NIMA effect directed toward
MHC antigens was divided into immunogenic and tolerogenic
reactivities. There was an unevenness in the acquisition and main-
tenance of microchimerism in offspring, which was not due solely
to differences in MHC gene inheritance. Although T cell replete
haploidentical transplantation is performed only when there is
positive microchimerism, the individual reactivity of the donor is
not evaluated at present. Therefore, our study is clinically relevant,
and T cell replete NIMA-mismatched haploidentical transplanta-
tion can be performed more safely in the future by evaluating
the responses of the IFN-γ-producing cells of the donor against
NIMA.
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